Tradjenta
Manufacturing · United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
United StatesWebsite
www.tradjenta.comRevenue
$5.2 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Tradjenta
Tradjenta is one of the newest drugs in the incretin mimetic class. This class of drugs has been on the market since 2006, and Boehringer Ingelheim gained FDA-approval for Tradjenta in August 2012. What is the problem with Tradjenta? The problem with Tradjenta is that it may have long-term side effects like pancreatic cancer. These diseases are some of the most severe, life-threatening side effects that any medication can cause. Our lawyers are concerned that Boehringer Ingelheim is not adequately warning about the potential risk. It is not unusual for new drugs to have unanticipated side effects, which is why many experts recommend taking precautions when new drugs are introduced. This is also why experts are so concerned about the evidence linking Tradjenta and pancreatic cancer.Explore more
Popular SearchesTradjentaBoehringer Ingelheim Pharmaceuticals IncSIC Code 28,283NAICS Code 32,325Show more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Tradjenta your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Tradjenta, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Tradjenta had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Tradjenta
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Tradjenta launches new products
Check out if Tradjenta is spiking on competitors!
Earning: See what the market has to say on Tradjenta recently announced quarterly report
Check if Tradjenta has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Tradjenta has new funding data
Recommended Actions
Find VP level buyers at Tradjenta
Find more new buyers
Compare Similar Companies to Tradjenta
Compare insights from companies similar to Tradjenta, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Tradjenta
$5.2M
11-50
Private
-
-
N/A
Company Profile Activity
Activity Insights
Tradjenta is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Tradjenta is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Tradjenta.
Tradjenta Tech Stack
A closer look at the technologies used by Tradjenta
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Tradjenta
Sign Up For FreeTo access detailed company insights
Tradjenta is one of the newest drugs in the incretin mimetic class. This class of drugs has been on the market since 2006, and Boehringer Ingelheim gained FDA-approval for Tradjenta in August 2012. What is the problem with Tradjenta? The problem with Tradjenta is that it may have long-term side effects like pancreatic cancer. These diseases are som... Read More
